Research and Option | PharmaShots

Sarepta Signs a Two-Year Research and Option Agreement with Codiak

Tuba Khan June 24, 2020

Shots: Codiak to receive up to $72.5M upfront, near-term license payments along with research funding and is eligible to receive development and regulatory milestone payments and tiered royalties on future […]Read More

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Genentech Collaborates with Scenic Biotech to Develop Novel Therapies Targeting Genetic Modifiers

Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Alexion’s Ultomiris (ravulizumab) Receives the CHMP’s Positive Opinion for its New Advanced Formulation

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Novartis’ Kisqali (ribociclib) Receives Highest Score on the ESMO Magnitude of Clinical Benefit Scale

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Tags : Research and Option